Research graph
References from Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Epidemiology and Natural History of Eosinophilic Esophagitis
10.1053/j.gastro.2017.06.067 · 2018 · External reference
Health‐Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review
10.1016/j.cgh.2017.06.036 · 2018 · External reference
Prevalence and Costs of Eosinophilic Esophagitis in the United States
10.1016/j.cgh.2024.09.031 · 2025 · External reference
Eosinophilic Esophagitis: A Comprehensive Review
10.1007/s12016-015-8501-z · 2016 · External reference
Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March
10.1016/j.jaip.2018.05.010 · 2018 · External reference
High Prevalence of Eosinophilic Gastrointestinal Disorders in Patients With Atopic Disease
10.1016/j.anai.2024.12.001 · 2025 · External reference
Food Allergy Characteristics Associated With Coexisting Eosinophilic Esophagitis in FARE Registry Participants
2023 · External reference
The Role of Food Allergy in Eosinophilic Esophagitis
10.2147/jaa.s238565 · 2020 · External reference
Dietary Therapy for Eosinophilic Esophagitis: Chances and Limitations in the Clinical Practice
10.1080/17474124.2020.1791084 · 2020 · External reference
Assessing Adherence and Barriers to Long‐Term Elimination Diet Therapy in Adults With Eosinophilic Esophagitis
10.1007/s10620-018-5045-0 · 2018 · External reference
One‐Food Versus 4‐Food Elimination Diet for Pediatric Eosinophilic Esophagitis: A Multisite Randomized Trial
10.1016/j.jaci.2024.08.023 · 2025 · External reference
One‐Food Versus Six‐Food Elimination Diet Therapy for the Treatment of Eosinophilic Oesophagitis: A Multicentre, Randomised, Open‐Label Trial
10.1016/s2468-1253(23)00012-2 · 2023 · External reference
Long‐Term Efficacy of Proton Pump Inhibitors as a Treatment Modality for Eosinophilic Esophagitis
10.1016/j.dld.2022.03.006 · 2022 · External reference
Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis
10.1016/j.cgh.2018.05.051 · 2019 · External reference
Efficacy of Therapy for Eosinophilic Esophagitis in Real‐World Practice
10.1016/j.cgh.2020.01.024 · 2020 · External reference
Medical Treatment of Eosinophilic Esophagitis
2023 · External reference
Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time‐Dependent Manner
10.1053/j.gastro.2013.08.015 · 2013 · External reference
A Phenotypic Analysis Shows That Eosinophilic Esophagitis Is a Progressive Fibrostenotic Disease
10.1016/j.gie.2013.10.027 · 2014 · External reference
The Natural Course of Eosinophilic Esophagitis and Long‐Term Consequences of Undiagnosed Disease in a Large Cohort
10.1038/s41395-018-0052-5 · 2018 · External reference
Eosinophilic Oesophagitis Endotype Classification by Molecular, Clinical, and Histopathological Analyses: A Cross‐Sectional Study
10.1016/s2468-1253(18)30096-7 · 2018 · External reference
Esophageal Dilation With Either Bougie or Balloon Technique as a Treatment for Eosinophilic Esophagitis: A Systematic Review and Meta‐Analysis
10.1016/j.gie.2017.04.028 · 2017 · External reference
Precise and in Situ Genetic Humanization of 6 Mb of Mouse Immunoglobulin Genes
10.1073/pnas.1323896111 · 2014 · External reference
Mice With Megabase Humanization of Their Immunoglobulin Genes Generate Antibodies as Efficiently as Normal Mice
10.1073/pnas.1324022111 · 2014 · External reference
Dual Blockade of IL‐4 and IL‐13 With Dupilumab, an IL‐4Rα Antibody, Is Required to Broadly Inhibit Type 2 Inflammation
10.1111/all.14151 · 2020 · External reference
Dupilumab in Adults and Adolescents With Eosinophilic Esophagitis
10.1056/nejmoa2205982 · 2022 · External reference
Efficacy and Safety of Dupilumab up to 52 Weeks in Adults and Adolescents With Eosinophilic Oesophagitis (LIBERTY EoE TREET Study): A Multicentre, Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Trial
10.1016/s2468-1253(23)00204-2 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Psychometric Evaluation of the Dysphagia Symptom Questionnaire for Adults and Adolescents With Eosinophilic Esophagitis
2024 · External reference
Development and Field Testing of a Novel Patient‐Reported Outcome Measure of Dysphagia in Patients With Eosinophilic Esophagitis
10.1111/apt.12413 · 2013 · External reference
Accuracy of the Eosinophilic Esophagitis Endoscopic Reference Score in Diagnosis and Determining Response to Treatment
10.1016/j.cgh.2015.08.040 · 2016 · External reference
Endoscopic Assessment of the Oesophageal Features of Eosinophilic Oesophagitis: Validation of a Novel Classification and Grading System
10.1136/gutjnl-2011-301817 · 2013 · External reference
Newly Developed and Validated Eosinophilic Esophagitis Histology Scoring System and Evidence That It Outperforms Peak Eosinophil Count for Disease Diagnosis and Monitoring
2017 · External reference
Phenotypes and Endotypes in Eosinophilic Esophagitis
10.1016/j.anai.2019.12.011 · 2020 · External reference
Association Between Atopic Manifestations and Eosinophilic Esophagitis: A Systematic Review and Meta‐Analysis
10.1016/j.anai.2017.02.006 · 2017 · External reference
Prevalence of Atopic Comorbidities in Eosinophilic Esophagitis: A Case‐Control Study of 449 Patients
10.1016/j.jaad.2016.08.068 · 2017 · External reference
Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta‐Analysis
10.1016/j.cgh.2015.07.041 · 2016 · External reference
Eosinophilic Esophagitis Phenotypes: Ready for Prime Time?
10.1111/pai.12715 · 2017 · External reference
Predictors of Response to Steroid Therapy for Eosinophilic Esophagitis and Treatment of Steroid‐Refractory Patients
10.1016/j.cgh.2014.07.034 · 2015 · External reference
Longitudinal Perspective on Managing Refractory Eosinophilic Esophagitis
10.1016/j.jaip.2015.06.024 · 2015 · External reference
Dupilumab Demonstrated Efficacy and Was Well Tolerated Regardless of Prior Use of Swallowed Topical Corticosteroids in Adolescent and Adult Patients With Eosinophilic Oesophagitis: A Subgroup Analysis of the Phase 3 LIBERTY EoE TREET Study
10.1136/gutjnl-2023-330220 · 2024 · External reference
Dupilumab Is Efficacious for Eosinophilic Esophagitis Irrespective of Prior Swallowed Budesonide or Fluticasone, or Prior Treatments Used Alongside Swallowed Topical Corticosteroids: Results From the Phase 3, Randomized, Placebo‐Controlled, LIBERTY EoE TREET Trial
10.1080/17474124.2025.2461516 · 2025 · External reference
Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications
10.1007/s12016-019-08733-0 · 2019 · External reference
Systematic Review With Meta‐Analysis: Endoscopic Dilation Is Highly Effective and Safe in Children and Adults With Eosinophilic Oesophagitis
10.1111/apt.14123 · 2017 · External reference
Evidence‐Based Treatments for Eosinophilic Esophagitis: Insights for the Clinician
10.1177/17562848211068665 · 2022 · External reference
Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype
10.1038/ajg.2015.399 · 2016 · External reference
ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
10.14309/ajg.0000000000003194 · 2025 · External reference
Real‐World Efficacy of Dupilumab in Severe, Treatment‐Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis
10.1016/j.cgh.2023.08.015 · 2024 · External reference
Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension
10.14309/ajg.0000000000003197 · 2024 · External reference
S455 Efficacy and Safety of the Selective Sphingosine 1‐Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study
10.14309/01.ajg.0000951460.86738.5a · 2023 · External reference
Etrasimod as a Treatment for Eosinophilic Oesophagitis (VOYAGE): A Double‐Blind, Placebo‐Controlled, Randomised, Phase 2 Trial
10.1016/s2468-1253(25)00062-7 · 2025 · External reference
